^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSI-H/dMMR + TMB-L

    i
    Other names: MSI | Microsatellite instability, TMB | Tumor Mutational Burden
    Related biomarkers:
    Expression
    Mutation
    Others
    9ms
    Large-Scale Cancer Genomic Analysis Reveals Significant Disparities Between Microsatellite Instability and Tumor Mutational Burden. (PubMed, Cancer Epidemiol Biomarkers Prev)
    These findings suggest that distinct or combined biomarkers should be considered for immunotherapy in human cancers because notable discrepancies exist between MSI-H and TMB-H across different cancer types.
    Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A) • ARID1B (AT-Rich Interaction Domain 1B)
    |
    TMB-H • MSI-H/dMMR • ARID1A mutation • TMB-L • MSI-H/dMMR + TMB-L
    over1year
    Validation of an integrative pan-solid tumor predictor of pembrolizumab monotherapy benefit (AACR 2023)
    These results confirm the pan-solid tumor PD-(L)1 monotherapy predictive nature of the IRS biomarker.
    Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • TOP2A (DNA topoisomerase 2-alpha) • ADAM12 (ADAM Metallopeptidase Domain 12)
    |
    PD-L1 expression • TMB-H • TMB-L • MSI-H/dMMR + TMB-L • TOP2A expression
    |
    Keytruda (pembrolizumab)